c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300

Akihiro Tomita, Masayuki Towatari, Shinobu Tsuzuki, Fumihiko Hayakawa, Hiroshi Kosugi, Katsuyuki Tamai, Toshiaki Miyazaki, Tomohiro Kinoshita, Hidehiko Saito

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Transcription factor c-Myb plays important roles in cell survival and differentiation in immature hematopoietic cells. Here we demonstrate that c-Myb is acetylated at the carboxyl-terminal conserved domain by histone acetyltransferase p300 both in vitro and in vivo. The acetylation sites in vivo have been located at the lysine residues of the conserved domain (K471, K480, K485) by the use of the mutant Myb (Myb-KAmut), in which all three lysine residues are substituted into alanine. Electrophoretic mobility shift assay reveals that Myb-KAmut shows higher DNA binding activity than wild type c-Myb and that acetylation of c-Myb in vitro by p300 causes dramatic increase in DNA binding activity. Accordingly, transactivation activity of both mim-1 and CD34 promoters by Myb-KAmut is higher than that driven by wild type c-Myb. Furthermore, the bromodomain of p300, in addition to the histone acetyltransferase (HAT) domain, is required for effective acetylation of c-Myb, and hGCN5 is revealed to be a factor acetyltransferase for c-Myb in vitro. We present a new manner of post-translational modification of the c-Myb protein and the potential significance of the acetylation in c-Myb.

Original languageEnglish
Pages (from-to)444-451
Number of pages8
JournalOncogene
Volume19
Issue number3
DOIs
Publication statusPublished - 20-01-2000
Externally publishedYes

Fingerprint

Acetylation
Histone Acetyltransferases
Lysine
Proto-Oncogene Proteins c-myb
Acetyltransferases
DNA
Electrophoretic Mobility Shift Assay
Post Translational Protein Processing
Alanine
Transcriptional Activation
Cell Differentiation
Cell Survival
Transcription Factors
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Tomita, A., Towatari, M., Tsuzuki, S., Hayakawa, F., Kosugi, H., Tamai, K., ... Saito, H. (2000). c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300. Oncogene, 19(3), 444-451. https://doi.org/10.1038/sj.onc.1203329
Tomita, Akihiro ; Towatari, Masayuki ; Tsuzuki, Shinobu ; Hayakawa, Fumihiko ; Kosugi, Hiroshi ; Tamai, Katsuyuki ; Miyazaki, Toshiaki ; Kinoshita, Tomohiro ; Saito, Hidehiko. / c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300. In: Oncogene. 2000 ; Vol. 19, No. 3. pp. 444-451.
@article{fe0d7e86af2b4bee9f708f0354ade23b,
title = "c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300",
abstract = "Transcription factor c-Myb plays important roles in cell survival and differentiation in immature hematopoietic cells. Here we demonstrate that c-Myb is acetylated at the carboxyl-terminal conserved domain by histone acetyltransferase p300 both in vitro and in vivo. The acetylation sites in vivo have been located at the lysine residues of the conserved domain (K471, K480, K485) by the use of the mutant Myb (Myb-KAmut), in which all three lysine residues are substituted into alanine. Electrophoretic mobility shift assay reveals that Myb-KAmut shows higher DNA binding activity than wild type c-Myb and that acetylation of c-Myb in vitro by p300 causes dramatic increase in DNA binding activity. Accordingly, transactivation activity of both mim-1 and CD34 promoters by Myb-KAmut is higher than that driven by wild type c-Myb. Furthermore, the bromodomain of p300, in addition to the histone acetyltransferase (HAT) domain, is required for effective acetylation of c-Myb, and hGCN5 is revealed to be a factor acetyltransferase for c-Myb in vitro. We present a new manner of post-translational modification of the c-Myb protein and the potential significance of the acetylation in c-Myb.",
author = "Akihiro Tomita and Masayuki Towatari and Shinobu Tsuzuki and Fumihiko Hayakawa and Hiroshi Kosugi and Katsuyuki Tamai and Toshiaki Miyazaki and Tomohiro Kinoshita and Hidehiko Saito",
year = "2000",
month = "1",
day = "20",
doi = "10.1038/sj.onc.1203329",
language = "English",
volume = "19",
pages = "444--451",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "3",

}

Tomita, A, Towatari, M, Tsuzuki, S, Hayakawa, F, Kosugi, H, Tamai, K, Miyazaki, T, Kinoshita, T & Saito, H 2000, 'c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300', Oncogene, vol. 19, no. 3, pp. 444-451. https://doi.org/10.1038/sj.onc.1203329

c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300. / Tomita, Akihiro; Towatari, Masayuki; Tsuzuki, Shinobu; Hayakawa, Fumihiko; Kosugi, Hiroshi; Tamai, Katsuyuki; Miyazaki, Toshiaki; Kinoshita, Tomohiro; Saito, Hidehiko.

In: Oncogene, Vol. 19, No. 3, 20.01.2000, p. 444-451.

Research output: Contribution to journalArticle

TY - JOUR

T1 - c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300

AU - Tomita, Akihiro

AU - Towatari, Masayuki

AU - Tsuzuki, Shinobu

AU - Hayakawa, Fumihiko

AU - Kosugi, Hiroshi

AU - Tamai, Katsuyuki

AU - Miyazaki, Toshiaki

AU - Kinoshita, Tomohiro

AU - Saito, Hidehiko

PY - 2000/1/20

Y1 - 2000/1/20

N2 - Transcription factor c-Myb plays important roles in cell survival and differentiation in immature hematopoietic cells. Here we demonstrate that c-Myb is acetylated at the carboxyl-terminal conserved domain by histone acetyltransferase p300 both in vitro and in vivo. The acetylation sites in vivo have been located at the lysine residues of the conserved domain (K471, K480, K485) by the use of the mutant Myb (Myb-KAmut), in which all three lysine residues are substituted into alanine. Electrophoretic mobility shift assay reveals that Myb-KAmut shows higher DNA binding activity than wild type c-Myb and that acetylation of c-Myb in vitro by p300 causes dramatic increase in DNA binding activity. Accordingly, transactivation activity of both mim-1 and CD34 promoters by Myb-KAmut is higher than that driven by wild type c-Myb. Furthermore, the bromodomain of p300, in addition to the histone acetyltransferase (HAT) domain, is required for effective acetylation of c-Myb, and hGCN5 is revealed to be a factor acetyltransferase for c-Myb in vitro. We present a new manner of post-translational modification of the c-Myb protein and the potential significance of the acetylation in c-Myb.

AB - Transcription factor c-Myb plays important roles in cell survival and differentiation in immature hematopoietic cells. Here we demonstrate that c-Myb is acetylated at the carboxyl-terminal conserved domain by histone acetyltransferase p300 both in vitro and in vivo. The acetylation sites in vivo have been located at the lysine residues of the conserved domain (K471, K480, K485) by the use of the mutant Myb (Myb-KAmut), in which all three lysine residues are substituted into alanine. Electrophoretic mobility shift assay reveals that Myb-KAmut shows higher DNA binding activity than wild type c-Myb and that acetylation of c-Myb in vitro by p300 causes dramatic increase in DNA binding activity. Accordingly, transactivation activity of both mim-1 and CD34 promoters by Myb-KAmut is higher than that driven by wild type c-Myb. Furthermore, the bromodomain of p300, in addition to the histone acetyltransferase (HAT) domain, is required for effective acetylation of c-Myb, and hGCN5 is revealed to be a factor acetyltransferase for c-Myb in vitro. We present a new manner of post-translational modification of the c-Myb protein and the potential significance of the acetylation in c-Myb.

UR - http://www.scopus.com/inward/record.url?scp=0034688345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034688345&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1203329

DO - 10.1038/sj.onc.1203329

M3 - Article

C2 - 10656693

AN - SCOPUS:0034688345

VL - 19

SP - 444

EP - 451

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 3

ER -